Key Points
- Director Geno Germano bought 2,609 Precision BioSciences shares at an average price of $6.28, investing $16,384.52 and increasing his direct ownership by 5.81% to 47,492 shares.
- Precision BioSciences reported a quarterly loss of $1.26 per share, missing the consensus estimate of an $0.80 loss; analysts project a full-year loss of $3.33 per share.
- Analyst sentiment is mixed but leans positive, with four Buy ratings and one Sell rating producing a “Moderate Buy” consensus and a $32.25 average price target, while institutional investors own 37.99% of the stock.
Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) Director Geno Germano purchased 2,609 shares of the company's stock in a transaction dated Friday, September 25th. The shares were purchased at an average cost of $6.28 per share, for a total transaction of $16,384.52. Following the transaction, the director directly owned 47,492 shares in the company, valued at approximately $298,249.76. The trade was a 5.81% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.
Precision BioSciences Price Performance
Shares of NASDAQ:DTIL opened at $6.18 on Wednesday. The firm has a market capitalization of $170.58 million, a PE ratio of -2.21 and a beta of 1.24. The company has a quick ratio of 12.82, a current ratio of 12.82 and a debt-to-equity ratio of 0.50. The company has a 50-day moving average price of $7.34 and a two-hundred day moving average price of $7.20. Precision BioSciences, Inc. has a twelve month low of $3.53 and a twelve month high of $9.62.
Precision BioSciences (NASDAQ:DTIL - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.46). Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 72.52%. Equities analysts forecast that Precision BioSciences, Inc. will post -3.33 EPS for the current year.
Wall Street Analysts Forecast Growth
DTIL has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Precision BioSciences in a report on Wednesday, August 5th. HC Wainwright reissued a "buy" rating on shares of Precision BioSciences in a research note on Monday, August 3rd. Wall Street Zen cut Precision BioSciences from a "hold" rating to a "sell" rating in a research note on Saturday, August 8th. Finally, Oppenheimer assumed coverage on shares of Precision BioSciences in a report on Tuesday, June 9th. They issued an "outperform" rating and a $20.00 price target on the stock. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $32.25.
View Our Latest Stock Report on DTIL
Institutional Trading of Precision BioSciences
Several institutional investors have recently bought and sold shares of the company. Engineers Gate Manager LP purchased a new stake in shares of Precision BioSciences during the second quarter valued at approximately $164,000. Squarepoint Ops LLC grew its holdings in shares of Precision BioSciences by 212.7% in the second quarter. Squarepoint Ops LLC now owns 137,106 shares of the company's stock worth $1,078,000 after acquiring an additional 93,258 shares during the period. Corient Private Wealth LP grew its stake in shares of Precision BioSciences by 70.4% during the 2nd quarter. Corient Private Wealth LP now owns 245,058 shares of the company's stock valued at $1,926,000 after purchasing an additional 101,206 shares during the period. Bank of New York Mellon Corp bought a new stake in Precision BioSciences during the second quarter valued at approximately $467,000. Finally, Bank of America Corp DE grew its position in shares of Precision BioSciences by 167.6% during the 1st quarter. Bank of America Corp DE now owns 27,416 shares of the company's stock valued at $151,000 after acquiring an additional 17,172 shares during the period. 37.99% of the stock is owned by hedge funds and other institutional investors.
About Precision BioSciences
(
Get Free Report)
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
